drugset

drugset / Trial / NCT00868660

Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose

NCT00868660 ↗

Phase 1 Completed 66 enrolled Zealand Pharma

RandomizedSingle-groupQuadruple-blindTreatment

Summary

Healthy Normal Single Ascending Dose and Crohn's patient Multiple Ascending Dose

Timeline

Start: 2009-01
Primary completion: 2010-02
Completion: 2010-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glepaglutide	Peptide	—	Subcutaneous

Indications